Physician profile
Eric Neisch
NPI 1225046477
$4,784.48
in general payments reported to CMS, 2019-2025
23 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,533 · 2020: $754 · 2021: $836 · 2022: $617 · 2023: $416 · 2024: $159 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,354.64 | 2019-2025 | Evenity, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $924.16 | 2019-2024 | Jardiance, Synjardy |
| Novo Nordisk INC | $715.90 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $588.81 | 2019-2021 | |
| Glaxosmithkline, LLC. | $268.37 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $145.66 | 2021 | |
| Exact Sciences Corporation | $126.10 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $111.22 | 2019-2021 | |
| Pfizer INC. | $92.95 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $81.64 | 2019-2020 | |
| Welch Allyn | $60.24 | 2021 | |
| Genzyme Corporation | $51.60 | 2019-2021 | |
| Baxter Healthcare | $45.18 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $43.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $36.61 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mckesson Medical-Surgical, INC. | $25.00 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $23.77 | 2019 | |
| Horizon Therapeutics Plc | $22.62 | 2022 | |
| Abbvie INC. | $15.91 | 2025 | |
| Abbott Laboratories | $14.29 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.04 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.02 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Neisch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.